Developer docs
API playgroundTry for free, no card

Search company profiles

Syndax Pharmaceuticals

Full company profile

uuid000212e

Namestring
Syndax Pharmaceuticals
Legal namestring
Syndax Pharmaceuticals, Inc.
Websiteurl
syndax.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Syndax Pharmaceuticals is a commercial-stage oncology biopharmaceutical company founded in October 2005 by Peter Ordentlich, Ph.D., that develops first-in-class targeted therapies for acute leukemias and chronic graft-versus-host disease (GVHD). The company is publicly traded on Nasdaq under ticker SNDX and operates from New York City (headquartered at 730 3rd Avenue), with additional operations referenced in Waltham, Massachusetts. Its portfolio is anchored by two FDA-approved products: Revuforj (revumenib), a first-in-class selective menin inhibitor approved for relapsed or refractory KMT2A-rearranged acute leukemia in 2024 and for NPM1-mutated acute myeloid leukemia (AML) in October 2025; and Niktimvo (axatilimab-csfr), a first-in-class anti-CSF-1R monoclonal antibody approved for chronic GVHD in August 2024 and co-promoted with Incyte in the United States. The company also retains an entinostat program (a Class I HDAC inhibitor) that has been deprioritized and licensed to Eddingpharm for China and certain Asian countries, where it has received marketing approval.

The company's technology rests on two proprietary platforms: menin inhibition (disrupting the menin-KMT2A protein-protein interaction to halt leukemic cell transcription programs driven by HOX and MEIS genes) and anti-CSF-1R monoclonal antibody technology (blocking colony stimulating factor-1 receptor signaling to reduce disease-mediating monocytes and macrophages in fibrotic conditions). Clinical performance has been category-defining: Revuforj demonstrated 88% overall response rate and 71% composite complete remission rate in the SAVE trial in relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML; 97% composite CR rate in newly diagnosed NPM1m/KMT2Ar AML in combination with intensive chemotherapy; and 90% two-year overall survival as maintenance post-transplant versus a 51% historical comparator. Niktimvo delivered 74% overall response rate in the AGAVE-201 trial in chronic GVHD patients who failed prior therapies. The pipeline extends into earlier-line settings, maintenance therapy, combination regimens (including with venetoclax and azacitidine), and additional indications such as idiopathic pulmonary fibrosis for axatilimab.

Syndax generates revenue through direct U.S. commercialization of Revuforj via an enterprise field sales force targeting oncologists, hematologists, and transplant centers, plus collaboration revenue from the Incyte co-promotion of Niktimvo. International reach is delivered through partner channels: Specialised Therapeutics (Australia, New Zealand, Singapore, with TGA approval secured in 2026), the World Orphan Drug Alliance (managed access program covering Eurasia, Central/Southeast Europe, Middle East, Turkey, Latin America, and Africa), and Eddingpharm (entinostat in Asia). FY2025 revenue totaled $172.4 million (Revuforj net revenue $124.8M, Niktimvo collaboration revenue $42.4M), and Q1 2026 revenue of $64.9 million represented 224% year-over-year growth, with a $394 million cash position at year-end 2025 supporting continued investment in commercial scaling and pipeline expansion.

Short descriptiontext

Syndax Pharmaceuticals is a commercial-stage oncology biopharmaceutical company that develops and markets first-in-class targeted therapies for acute leukemias and chronic graft-versus-host disease, anchored by Revuforj (menin inhibitor) and Niktimvo (anti-CSF-1R antibody), serving U.S. and international oncology and transplant patients through direct sales and partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
menin inhibitor therapy, acute leukemia treatment, chronic graft-versus-host disease, targeted oncology therapeutics, hematology cancer drugs
Industry2 codes
PRIMARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Revuforj (revumenib) Sales
TypeOne Time License
Description

Revuforj is an FDA-approved menin inhibitor for treating relapsed or refractory KMT2Ar acute leukemia and NPM1m AML. The drug generated $124.8 million in full-year 2025 net revenue and $48.9 million in Q1 2026 net revenue. The company markets the drug directly through its commercial organization.

biospace.com
2Niktimvo (axatilimab) Collaboration Revenue
TypeLicensing Royalties
Description

Niktimvo is an FDA-approved anti-CSF-1R antibody for chronic graft-versus-host disease. Syndax co-promotes the drug with strategic partner Incyte. The company received $42.4 million in Niktimvo collaboration revenue for full-year 2025, and Niktimvo generated $151.6 million in revenue to partner Incyte. Niktimvo achieved $55.1 million in Q1 2026.

biospace.com
3Entinostat Licensing (China/Asia)
TypeLicensing Royalties
Description

Syndax maintains a license, development and commercialization agreement with Eddingpharm International Company Limited for entinostat in China and certain other Asian countries. The drug received marketing approval in China.

syndax.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Revuforj is a prescription pharmaceutical product with pricing subject to state reporting requirements
ModelOtherBilling cadenceOther
Notes

Wholesale Acquisition Cost (WAC) information is available through state disclosure forms as required for Colorado, Connecticut, and Vermont prescribers

syndax.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Revuforj
Description

FDA-approved menin inhibitor for treating relapsed or refractory acute leukemia with KMT2A translocation or NPM1 mutation

+2 more records
Core offering1 text field

Syndax Pharmaceuticals develops and commercializes first-in-class targeted oncology therapies, with two FDA-approved drugs on the U.S. market: Revuforj (revumenib), a selective menin inhibitor for relapsed/refractory KMT2A-rearranged acute leukemia and NPM1-mutated AML, and Niktimvo (axatilimab-csfr), an anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease. The company supplements direct product sales with co-promotion revenue (Incyte), ex-U.S. distribution partnerships, and licensing royalties on its deprioritized HDAC inhibitor entinostat in Asia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 88% overall response rate in relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML patients (SAVE trial)
+5 more records
Product overview1 text field

Syndax Pharmaceuticals is a commercial-stage oncology company with two FDA-approved cancer therapies: Revuforj® (revumenib), a first-in-class menin inhibitor approved for relapsed or refractory KMT2A-rearranged and NPM1-mutated acute leukemias, and Niktimvo™ (axatilimab-csfr), a first-in-class anti-CSF-1R antibody approved for chronic graft-versus-host disease. The company also has pipeline programs including revumenib in earlier-line settings and combination therapies, and axatilimab in idiopathic pulmonary fibrosis and frontline chronic GVHD. Entinostat, a Class I HDAC inhibitor, has been deprioritized with rights licensed to Eddingpharm for Asia. The company's focus areas include acute leukemias (KMT2Ar and NPM1m subtypes) and chronic GVHD.

Product and service3 records
1Revuforj (revumenib)
CategoryFDA-approved oncology drug (menin inhibitor)
Description

First-in-class selective menin inhibitor approved by the FDA for the treatment of adult and pediatric patients with relapsed or refractory KMT2A-rearranged acute leukemia (2024) and relapsed or refractory NPM1-mutated acute myeloid leukemia (October 2025). Revumenib works by disrupting the menin-KMT2A protein-protein interaction, turning off HOX and MEIS gene expression to halt leukemic cell growth. Generated $124.8M in FY2025 net revenue and was the highest first-year revenue AML product at $125M.

2Niktimvo (axatilimab-csfr)
CategoryFDA-approved oncology drug (anti-CSF-1R monoclonal antibody)
Description

First-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking monoclonal antibody approved by the FDA for chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy. Axatilimab reduces disease-mediating macrophages and their monocyte precursors to address the fibrotic disease process underlying chronic GVHD. Co-promoted with Incyte in the United States; generated $42.4M collaboration revenue in FY2025 with $151.6M in partner Incyte sales.

3Entinostat (SNDX-275)
CategoryLicensed HDAC inhibitor (deprioritized)
Description

Selective, oral, once-weekly Class I HDAC inhibitor previously studied in multiple solid tumors in combination with hormone therapy and checkpoint inhibitors. Entinostat is thought to re-sensitize cells to endocrine therapy and demonstrates synergistic anti-tumor activity with immune checkpoint inhibitors. Development has been deprioritized; commercial rights in China and certain other Asian countries are licensed to Eddingpharm International Company Limited under a license, development and commercialization agreement, with marketing approval received in China.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-01
Description

Exclusive partnership to commercialize NiktimVO (axatilimab) in Australia, New Zealand, and Singapore. Specialised Therapeutics pursued reimbursement through the Pharmaceutical Benefits Scheme in Australia following TGA approval.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Strategic co-promotion partnership for Niktimvo (axatilimab-csfr) in the United States. Syndax and Incyte collaborate on commercialization with Incyte handling patient support through IncyteCARES program. The partnership leverages both companies' hematology/oncology commercial infrastructure.

3Eddingpharm International Company Limited
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensing agreement granting Eddingpharm exclusive rights to develop and commercialize entinostat in China and certain other Asian countries. Entinostat received marketing approval in China under this agreement.

syndax.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Collaboration for Syndax-WODA Managed Access Program providing revumenib to patients in regions where not yet commercially available. WODA provides the drug through its network of members on a named patient basis in parts of Eurasia, Central/Southeast Europe, Middle East, Turkey, Latin America, and Africa.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology company developing menin inhibitors (KO-539) for KMT2A-rearranged and NPM1-mutant acute leukemias — directly competing with Syndax's Revuforj in the same molecular target and indications.

TypeBroad incumbent
Description

Japanese global biopharma with strong antibody-drug conjugate and hematology/oncology pipeline; comparable as a specialty hematology/oncology innovator with similar first-in-class development focus.

TypeBroad incumbent
Description

Major oncology and immunology biopharma with broad hematology and transplant-related franchises; competes in adjacent specialty pharma indications including leukemia and post-transplant complications.

TypeBroad incumbent
Description

Large diversified biopharma with significant oncology and hematology presence including active menin inhibition research through partnerships; competes broadly with Syndax in acute leukemia treatment settings.

TypeDirect peer
Description

Strategic partner that co-promotes Niktimvo with Syndax in the U.S., but also a competitor in chronic GVHD through ruxolitinib (Jakafi) — providing both commercial leverage and overlap in target indications.

TypeDirect peer
Description

Markets Rezurock (belumosudil) for chronic graft-versus-host disease after transplant, directly competing with Syndax's Niktimvo in the same indication and third-line-plus patient population.

7Forma Therapeutics (Novo Nordisk)
TypeEmerging player
Description

Developed FTX-6058 and a menin inhibitor program for AML before being acquired by Novo Nordisk; overlaps with Syndax in the menin inhibition mechanism and hematologic oncology target space.

TypeEmerging player
Description

Clinical-stage biotech developing FHD-286, a menin inhibitor for AML — competing with Syndax's Revuforj in the same molecular target space with a focused but earlier-stage pipeline.

9Bristol-Myers Squibb
TypeBroad incumbent
Description

Large oncology incumbent with broad hematology portfolio and active menin inhibitor research (incoming Head of R&D Nick Botwood came from BMS); competes broadly across AML/GVHD treatment paradigms.

TypeDirect peer
Description

Specialty biopharma developing ziftomenib, a menin inhibitor for KMT2A-rearranged AML, in direct competition with Syndax's Revuforj across the same genetic subtype and indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syndax Pharmaceuticals

Oncology Pharmaceuticalssyndax.com

Syndax Pharmaceuticals is a commercial-stage oncology biopharmaceutical company that develops and markets first-in-class targeted therapies for acute leukemias and chronic graft-versus-host disease, anchored by Revuforj (menin inhibitor) and Niktimvo (anti-CSF-1R antibody), serving U.S. and international oncology and transplant patients through direct sales and partnerships.

What Syndax Pharmaceuticals does

Syndax Pharmaceuticals is a commercial-stage oncology biopharmaceutical company founded in October 2005 by Peter Ordentlich, Ph.D., that develops first-in-class targeted therapies for acute leukemias and chronic graft-versus-host disease (GVHD). The company is publicly traded on Nasdaq under ticker SNDX and operates from New York City (headquartered at 730 3rd Avenue), with additional operations referenced in Waltham, Massachusetts. Its portfolio is anchored by two FDA-approved products: Revuforj (revumenib), a first-in-class selective menin inhibitor approved for relapsed or refractory KMT2A-rearranged acute leukemia in 2024 and for NPM1-mutated acute myeloid leukemia (AML) in October 2025; and Niktimvo (axatilimab-csfr), a first-in-class anti-CSF-1R monoclonal antibody approved for chronic GVHD in August 2024 and co-promoted with Incyte in the United States. The company also retains an entinostat program (a Class I HDAC inhibitor) that has been deprioritized and licensed to Eddingpharm for China and certain Asian countries, where it has received marketing approval.

The company's technology rests on two proprietary platforms: menin inhibition (disrupting the menin-KMT2A protein-protein interaction to halt leukemic cell transcription programs driven by HOX and MEIS genes) and anti-CSF-1R monoclonal antibody technology (blocking colony stimulating factor-1 receptor signaling to reduce disease-mediating monocytes and macrophages in fibrotic conditions). Clinical performance has been category-defining: Revuforj demonstrated 88% overall response rate and 71% composite complete remission rate in the SAVE trial in relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML; 97% composite CR rate in newly diagnosed NPM1m/KMT2Ar AML in combination with intensive chemotherapy; and 90% two-year overall survival as maintenance post-transplant versus a 51% historical comparator. Niktimvo delivered 74% overall response rate in the AGAVE-201 trial in chronic GVHD patients who failed prior therapies. The pipeline extends into earlier-line settings, maintenance therapy, combination regimens (including with venetoclax and azacitidine), and additional indications such as idiopathic pulmonary fibrosis for axatilimab.

Syndax generates revenue through direct U.S. commercialization of Revuforj via an enterprise field sales force targeting oncologists, hematologists, and transplant centers, plus collaboration revenue from the Incyte co-promotion of Niktimvo. International reach is delivered through partner channels: Specialised Therapeutics (Australia, New Zealand, Singapore, with TGA approval secured in 2026), the World Orphan Drug Alliance (managed access program covering Eurasia, Central/Southeast Europe, Middle East, Turkey, Latin America, and Africa), and Eddingpharm (entinostat in Asia). FY2025 revenue totaled $172.4 million (Revuforj net revenue $124.8M, Niktimvo collaboration revenue $42.4M), and Q1 2026 revenue of $64.9 million represented 224% year-over-year growth, with a $394 million cash position at year-end 2025 supporting continued investment in commercial scaling and pipeline expansion.

Syndax Pharmaceuticals firmographics

Firmographics
Name
Syndax Pharmaceuticals
Legal name
Syndax Pharmaceuticals, Inc.
Website
https://syndax.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
251–500 employees
Short description
Syndax Pharmaceuticals is a commercial-stage oncology biopharmaceutical company that develops and markets first-in-class targeted therapies for acute leukemias and chronic graft-versus-host disease, anchored by Revuforj (menin inhibitor) and Niktimvo (anti-CSF-1R antibody), serving U.S. and international oncology and transplant patients through direct sales and partnerships.
Ownership category
akta.pro rank

Syndax Pharmaceuticals industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Menin inhibitor therapy
  • Acute leukemia treatment
  • Chronic graft-versus-host disease
  • Targeted oncology therapeutics
  • Hematology cancer drugs

Where Syndax Pharmaceuticals is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Syndax Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Revuforj (revumenib) Sales: Revuforj is an FDA-approved menin inhibitor for treating relapsed or refractory KMT2Ar acute leukemia and NPM1m AML. The drug generated $124.8 million in full-year 2025 net revenue and $48.9 million in Q1 2026 net revenue. The company markets the drug directly through its commercial organization.
  2. Niktimvo (axatilimab) Collaboration Revenue: Niktimvo is an FDA-approved anti-CSF-1R antibody for chronic graft-versus-host disease. Syndax co-promotes the drug with strategic partner Incyte. The company received $42.4 million in Niktimvo collaboration revenue for full-year 2025, and Niktimvo generated $151.6 million in revenue to partner Incyte. Niktimvo achieved $55.1 million in Q1 2026.
  3. Entinostat Licensing (China/Asia): Syndax maintains a license, development and commercialization agreement with Eddingpharm International Company Limited for entinostat in China and certain other Asian countries. The drug received marketing approval in China.

Pricing tiers

ModelBillingPrice
OtherOtherRevuforj is a prescription pharmaceutical product with pricing subject to state reporting requirements

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Syndax Pharmaceuticals product offering

Product offering

Core offering

Syndax Pharmaceuticals develops and commercializes first-in-class targeted oncology therapies, with two FDA-approved drugs on the U.S. market: Revuforj (revumenib), a selective menin inhibitor for relapsed/refractory KMT2A-rearranged acute leukemia and NPM1-mutated AML, and Niktimvo (axatilimab-csfr), an anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease. The company supplements direct product sales with co-promotion revenue (Incyte), ex-U.S. distribution partnerships, and licensing royalties on its deprioritized HDAC inhibitor entinostat in Asia.

Product overview

Syndax Pharmaceuticals is a commercial-stage oncology company with two FDA-approved cancer therapies: Revuforj® (revumenib), a first-in-class menin inhibitor approved for relapsed or refractory KMT2A-rearranged and NPM1-mutated acute leukemias, and Niktimvo™ (axatilimab-csfr), a first-in-class anti-CSF-1R antibody approved for chronic graft-versus-host disease. The company also has pipeline programs including revumenib in earlier-line settings and combination therapies, and axatilimab in idiopathic pulmonary fibrosis and frontline chronic GVHD. Entinostat, a Class I HDAC inhibitor, has been deprioritized with rights licensed to Eddingpharm for Asia. The company's focus areas include acute leukemias (KMT2Ar and NPM1m subtypes) and chronic GVHD.

Differentiator

Problem solved

Functional benefit

Brands

  • Revuforj: FDA-approved menin inhibitor for treating relapsed or refractory acute leukemia with KMT2A translocation or NPM1 mutation
  • Niktimvo
  • SyndAccess

Products and services

  • Revuforj (revumenib) First-in-class selective menin inhibitor approved by the FDA for the treatment of adult and pediatric patients with relapsed or refractory KMT2A-rearranged acute leukemia (2024) and relapsed or refractory NPM1-mutated acute myeloid leukemia (October 2025). Revumenib works by disrupting the menin-KMT2A protein-protein interaction, turning off HOX and MEIS gene expression to halt leukemic cell growth. Generated $124.8M in FY2025 net revenue and was the highest first-year revenue AML product at $125M.
  • Niktimvo (axatilimab-csfr) First-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking monoclonal antibody approved by the FDA for chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy. Axatilimab reduces disease-mediating macrophages and their monocyte precursors to address the fibrotic disease process underlying chronic GVHD. Co-promoted with Incyte in the United States; generated $42.4M collaboration revenue in FY2025 with $151.6M in partner Incyte sales.
  • Entinostat (SNDX-275) Selective, oral, once-weekly Class I HDAC inhibitor previously studied in multiple solid tumors in combination with hormone therapy and checkpoint inhibitors. Entinostat is thought to re-sensitize cells to endocrine therapy and demonstrates synergistic anti-tumor activity with immune checkpoint inhibitors. Development has been deprioritized; commercial rights in China and certain other Asian countries are licensed to Eddingpharm International Company Limited under a license, development and commercialization agreement, with marketing approval received in China.

Quantifiable outcome

  • 88% overall response rate in relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML patients (SAVE trial)
  • +5 more outcomes

Companies that use Syndax Pharmaceuticals

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Syndax Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Syndax Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered regional, core and minor.

  • Specialised TherapeuticsregionalChannel Partner/ Reseller/ Distributor · 1 June 2025Exclusive partnership to commercialize NiktimVO (axatilimab) in Australia, New Zealand, and Singapore. Specialised Therapeutics pursued reimbursement through the Pharmaceutical Benefits Scheme in Australia following TGA approval.
  • IncytecoreStrategic or Co-development Partner · 1 January 2024Strategic co-promotion partnership for Niktimvo (axatilimab-csfr) in the United States. Syndax and Incyte collaborate on commercialization with Incyte handling patient support through IncyteCARES program. The partnership leverages both companies' hematology/oncology commercial infrastructure.
  • Eddingpharm International Company LimitedminorOEM/ Whitelabel/ Licensing PartnerLicensing agreement granting Eddingpharm exclusive rights to develop and commercialize entinostat in China and certain other Asian countries. Entinostat received marketing approval in China under this agreement.
  • World Orphan Drug Alliance (WODA)minorChannel Partner/ Reseller/ DistributorCollaboration for Syndax-WODA Managed Access Program providing revumenib to patients in regions where not yet commercially available. WODA provides the drug through its network of members on a named patient basis in parts of Eurasia, Central/Southeast Europe, Middle East, Turkey, Latin America, and Africa.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Syndax Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Kura Oncology: Clinical-stage oncology company developing menin inhibitors (KO-539) for KMT2A-rearranged and NPM1-mutant acute leukemias — directly competing with Syndax's Revuforj in the same molecular target and indications.
  • Incyte: Strategic partner that co-promotes Niktimvo with Syndax in the U.S., but also a competitor in chronic GVHD through ruxolitinib (Jakafi) — providing both commercial leverage and overlap in target indications.
  • Sanofi: Markets Rezurock (belumosudil) for chronic graft-versus-host disease after transplant, directly competing with Syndax's Niktimvo in the same indication and third-line-plus patient population.
  • Jazz Pharmaceuticals: Specialty biopharma developing ziftomenib, a menin inhibitor for KMT2A-rearranged AML, in direct competition with Syndax's Revuforj across the same genetic subtype and indication.

Broad incumbents

  • Daiichi Sankyo: Japanese global biopharma with strong antibody-drug conjugate and hematology/oncology pipeline; comparable as a specialty hematology/oncology innovator with similar first-in-class development focus.
  • AbbVie: Major oncology and immunology biopharma with broad hematology and transplant-related franchises; competes in adjacent specialty pharma indications including leukemia and post-transplant complications.
  • Pfizer: Large diversified biopharma with significant oncology and hematology presence including active menin inhibition research through partnerships; competes broadly with Syndax in acute leukemia treatment settings.
  • Bristol-Myers Squibb: Large oncology incumbent with broad hematology portfolio and active menin inhibitor research (incoming Head of R&D Nick Botwood came from BMS); competes broadly across AML/GVHD treatment paradigms.

Emerging players

  • Forma Therapeutics (Novo Nordisk): Developed FTX-6058 and a menin inhibitor program for AML before being acquired by Novo Nordisk; overlaps with Syndax in the menin inhibition mechanism and hematologic oncology target space.
  • Foghorn Therapeutics: Clinical-stage biotech developing FHD-286, a menin inhibitor for AML — competing with Syndax's Revuforj in the same molecular target space with a focused but earlier-stage pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Syndax Pharmaceuticals social profiles

Digital presence

Syndax Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syndax Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Syndax Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syndax Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syndax Pharmaceuticals

What does Syndax Pharmaceuticals do?

Syndax Pharmaceuticals develops and commercializes first-in-class targeted oncology therapies, with two FDA-approved drugs on the U.S. market: Revuforj (revumenib), a selective menin inhibitor for relapsed/refractory KMT2A-rearranged acute leukemia and NPM1-mutated AML, and Niktimvo (axatilimab-csfr), an anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease. The company supplements direct product sales with co-promotion revenue (Incyte), ex-U.S. distribution partnerships, and licensing royalties on its deprioritized HDAC inhibitor entinostat in Asia.

Is Syndax Pharmaceuticals a public or private company?

Syndax Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Syndax Pharmaceuticals founded?

Syndax Pharmaceuticals was founded in 2005. It employs 251 to 500 people.

Where is Syndax Pharmaceuticals based?

Syndax Pharmaceuticals is headquartered in New York, United States, in the North America region.

How does Syndax Pharmaceuticals make money?

Three revenue lines are on record. Revuforj (revumenib) Sales are the primary driver. The others are niktimvo (axatilimab) Collaboration Revenue and entinostat Licensing (China/Asia).

Who are Syndax Pharmaceuticals's main competitors?

Direct peers on record are Kura Oncology, Incyte, Sanofi and Jazz Pharmaceuticals. Broad incumbents are Daiichi Sankyo, AbbVie, Pfizer and Bristol-Myers Squibb. Emerging players are Forma Therapeutics (Novo Nordisk) and Foghorn Therapeutics.

Does Syndax Pharmaceuticals have an API?

No public API is recorded for Syndax Pharmaceuticals.

What industry is Syndax Pharmaceuticals in?

Syndax Pharmaceuticals's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaSyndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Biopharma Conference 2026 TranscriptSyndax Pharmaceuticals presented at the UBS Global Biopharma Conference 2026, with CEO Michael Metzger and CMO Nicholas Botwood discussing its two commercial-stage programs. Revuforj, a menin inhibitor, has been on the market for over a year with continued sales growth, while Niktimvo for GVHD may move to a frontline setting with data expected next year.PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXPomerantz LLP is investigating claims on behalf of Syndax Pharmaceuticals investors, alleging securities fraud. The investigation follows Syndax's October 12, 2026 announcement that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint, causing the stock to fall 2.59% to $16.55.FinancialContent Business PageINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXPomerantz LLP is investigating claims on behalf of Syndax Pharmaceuticals investors, alleging securities fraud or unlawful business practices. The investigation follows Syndax's October 12, 2026 announcement that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint, causing the stock to fall 2.59% to $16.55.GlobeNewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXPomerantz LLP is investigating claims on behalf of Syndax Pharmaceuticals investors, alleging securities fraud. The investigation follows Syndax's October 12, 2026 announcement that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint, causing the stock to fall 2.59% to $16.55.FinancialContent Business PageSyndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Syndax Pharmaceuticals announced that CFO Aaron Ondrey received an inducement award to purchase up to 270,000 shares of common stock, with an exercise price of $9.55 per share. The award vests over four years, with 25% vesting on the one-year anniversary and 1/48th monthly thereafter, subject to continued service.GlobeNewswireSyndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Syndax Pharmaceuticals announced that CFO Aaron Ondrey received an inducement stock option to purchase up to 270,000 shares, exercisable at $9.55 per share. The award vests over four years, with 25% vesting after one year and the remainder monthly thereafter, subject to continued service.Stock TitanSyndax grants CFO options for up to 270,000 sharesSyndax Pharmaceuticals granted CFO Aaron Ondrey an inducement option to buy up to 270,000 shares at $9.55 each, vesting over four years. The award was approved under NASDAQ Listing Rule 5635(c)(4) in connection with his November 2, 2026 hiring.PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXPomerantz LLP is investigating claims on behalf of Syndax Pharmaceuticals investors, alleging securities fraud. The investigation follows Syndax's October 12, 2026 announcement that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint, causing the stock to fall 2.59% to $16.55.PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXPomerantz LLP is investigating claims on behalf of Syndax Pharmaceuticals investors over potential securities fraud. The investigation follows Syndax's October 12, 2026 announcement that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint, causing the stock to fall 2.59% to $16.55.Simply Wall StSyndax Pharmaceuticals Is Down 51% Even Though Sales RoseSyndax Pharmaceuticals shares fell 50.9% in 2026 after axatilimab failed its Phase 2 IPF trial, despite Q3 revenue of $83.3 million and a less negative net margin of 59.3%. The stock now trades at $10.45, with analysts debating whether the drop reflects short-term disappointment or a deeper valuation issue.